Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.
Researchers at UT Southwestern Medical Center have discovered that drugs commonly used to treat psychiatric illnesses and blood disorders in humans may protect the brain cells that die in people with Huntington's disease, possibly delaying the onset and slowing the progression of the disease.
Generic antipsychotic drugs can protect brain cells from a virus that causes a fatal nervous system disorder, according to research conducted at Brown University and Case Western Reserve University.
The researchers studied the brain waves of normal and schizophrenic patients as they responded to images. Those with the disorder showed no electrical activity in a certain frequency-the “gamma” range, from 30 to 100 brain waves per second-that healthy brain cells use to exchange information about the environment and form mental impressions.
University of Illinois at Chicago researchers are comparing two drugs used to treat pediatric bipolar disorder patients to evaluate how the drugs affect brain function in children with the disorder.
Researchers from the Johns Hopkins Children's Center say a group of drugs known as "atypical antipsychotics" that are commonly used to treat children with aggression, bipolar disorder, and schizophrenia may trigger insulin resistance, a condition that increases the risk of developing Type 2 diabetes and heart disease later in life.
AstraZeneca has announced important new data at the 4th European Stanley Foundation Conference on Bipolar Disorder, which show Seroquel is significantly more effective than placebo in treating patients with rapid-cycling bipolar disorder and is also well-tolerated in this difficult to treat patient population.
Pfizer has announced that the U.S. Food and Drug Administration (FDA) has approved the use of its atypical antipsychotic Geodon(R) (ziprasidone HCI) for the treatment of acute bipolar mania including manic and mixed episodes.
Janssen Pharmaceutica, the maker of RISPERDAL® (risperidone), the most frequently prescribed antipsychotic medication in the U.S., has sent a letter to health care providers to clarify the risks involved with the use of RISPERDAL®.
Doctors are reporting some success in treating one of the most troubling symptoms of dementias such as Alzheimer’s disease. A drug commonly used to treat schizophrenia and other psychotic disorders appears effective at reducing actions like screaming at or slapping caregivers – agitated behaviors that occur in as many as half of patients.
A member of a class of drugs that are widely prescribed for abnormal behavioral symptoms in Alzheimer’s – but not often studied in people with the degenerative brain disease – proved to be effective and well tolerated in treating agitation in people with severe Alzheimer’s
Scientists funded by the UK's largest biomedical research charity, The Wellcome Trust, have developed a drink that enhances the effectiveness of medication given to treat psychiatric illnesses such as mania and schizophrenia.
Solvay has re-evaluated the commercial potential of bifeprunox, a Solvay compound in clinical development for the treatment of schizophrenia . Bifeprunox additionally has the potential to be developed in other disorders, i.e. bipolar disorder.
Patients with schizophrenia who fail to take their medicines as prescribed are over one-and-a-half times as likely to be rehospitalised and use in-patient services as patients who stick to their medication regimen. Non-adherence predicted an excess annual cost per patient of £5000 for total service use.
Patients with severe and persistent mental illness treated with antipsychotic medications reported positive changes in diet, exercise, stress management, improved sleep, and increased confidence in maintaining these lifestyle changes after participating in the Solutions for Wellness Personalized Program (SFWPP), new data show.
Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins.
Johnson & Johnson today announced sales for the first quarter of $11.6 billion, an increase of 17.7% over the prior year. The increase represented operational growth of 12.3% and a currency impact of 5.4%. Domestic sales were up 15.1%, while international sales increased 21.8%, including operational growth of 7.8% and a positive currency impact of 14.0%.
Researchers at Duke University Medical Center have found that a new generation of medications called "atypical antipsychotics" can significantly lower the risk of violent behavior in people with schizophrenia who are being treated in community-based centers.
Physicians have a new fast-acting option for controlling the potentially crippling effects of acute agitation in patients suffering with schizophrenia and bipolar mania. The U.S. Food and Drug Administration (FDA) has approved Zyprexa® IntraMuscular (olanzapine for injection), an injectable form of Lilly's top-selling medication.